In the US, Durvalumab (durvalumab systemic) is a member of the drug class anti-PD-1 monoclonal antibodies and is used to treat Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Urothelial Carcinoma.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Antineoplastic agent: Monoclonal antibody
Immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 kappa-chain, dimer (USAN)
- Durvalumabum (Latin)
- Durvalumab (German)
- Durvalumab (French)
- Durvalumab (Spanish)
- Durvalumab (OS: USAN)
- MEDI 4736 (ChemID) (IS)
- MEDI4736 (ChemID) (IS)
- MEDI-4736 (Stoffliste) (IS)
- UNII-28X28X9OKV (ChemID) (IS)
AstraZeneca, United States
- Imfinzi 120mg/2.4ml
- Imfinzi 500mg/10ml
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.